<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04435821</url>
  </required_header>
  <id_info>
    <org_study_id>52830</org_study_id>
    <nct_id>NCT04435821</nct_id>
  </id_info>
  <brief_title>PET/MRI in the Diagnosis of Pediatric Chronic Pain</brief_title>
  <official_title>Use of PET/MRI in the Diagnosis of Pediatric Chronic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      [18F]FTC-146 is a sigma-1 receptor detector and is an experimental radiotracer. Several&#xD;
      studies have implicated involvement of sigma-1 receptors in generation and perpetuation of&#xD;
      chronic pain conditions, while others are investigating anti sigma-1 receptor drugs for&#xD;
      treatment of chronic pain. Using [18F]-FTC-146 and PET/MRI, we hope to learn what is the best&#xD;
      approach to identify the source of pain generation and characterize the disease in pediatric&#xD;
      patients with chronic pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is estimated that 20% to 35% of children and adolescents worldwide are affected by chronic&#xD;
      pain. As a result of chronic pain, children may miss school, withdraw from social activities,&#xD;
      and develop internalizing behaviors. Therefore, accurately identifying the cause of a child's&#xD;
      pain is important for both proper treatment of the pain and to prevent problems secondary to&#xD;
      the chronic pain. Evidence in the literature points strongly toward an involvement of the&#xD;
      sigma-1 receptor in neurogenic inflammation, which is known to be an important&#xD;
      pathophysiological mechanism for maintenance and perpetuation of chronic neuropathic pain.&#xD;
      The investigators hope to image and identify activated pain pathways in pediatric pain&#xD;
      paitents using a radiolabeled biomarker for increased S1R expression. By localizing and&#xD;
      quantifying areas of increased S1R expression to sites of augmented nociceptive activity&#xD;
      using hybrid molecular/anatomic imaging techniques, we will objectively identify sites of&#xD;
      neurogenic inflammatory activity and pain generation. The ability to image the changes&#xD;
      associated with chronic pain generating pathologies provides us with a tool to identify and&#xD;
      measure the intensity of the pathology. Imaging S1R expression in chronic pain states in&#xD;
      pediatric patients would be both novel in its application and extremely powerful in better&#xD;
      characterizing pediatric pain.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 19, 2020</start_date>
  <completion_date type="Anticipated">August 2025</completion_date>
  <primary_completion_date type="Anticipated">August 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Pediatric Chronic Pain Patients</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>[18F]FTC-146 Biodistribution in Pain Patients [18F]FTC-146 Biodistribution in Pain Patients [18F]FTC-146 Biodistribution in Pain Patients</measure>
    <time_frame>3 hours</time_frame>
    <description>Biodistribution of [18F]FTC-146 represented as Standardized Uptake Value max (SUVmax) in pain patients.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Pain</condition>
  <condition>Pediatric Disorder</condition>
  <condition>Neuropathic Pain</condition>
  <condition>Nociceptive Pain</condition>
  <arm_group>
    <arm_group_label>Pediatric Chronic Pain Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals 11-18 years old, with chronic pain (lasting at least 2 months).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]FTC-146</intervention_name>
    <description>Participants will be injected with 0.08 mCi/kg [18F]FTC-146. A whole-body PET/MRI scan will be performed after injection.</description>
    <arm_group_label>Pediatric Chronic Pain Patients</arm_group_label>
    <other_name>S1R</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  11-18 years old.&#xD;
&#xD;
          -  Chronic pain (nociceptive, neuropathic or mixed pain) lasting at least 2 months.&#xD;
&#xD;
          -  Pain level of at least 4/10 on a 0-10 Comparative Pain Scale (reported at time of&#xD;
             screening).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  MRI incompatible&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandip Biswal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 15, 2020</study_first_submitted>
  <study_first_submitted_qc>June 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 17, 2020</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Sandip Biswal</investigator_full_name>
    <investigator_title>Associate Professor of Radiology</investigator_title>
  </responsible_party>
  <keyword>PET/MRI</keyword>
  <keyword>Pediatric Chronic Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Nociceptive Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

